ClearPoint Neuro (CLPT, Financial) is advancing its ClearPoint Prism Neuro Laser Therapy System through a partnership with Clinical Laserthermia Systems. The latter has completed its 510(k) application for FDA approval, aiming to expand the system’s use to include 1.5 T MRI guidance. This development is expected to broaden the system's applications, which are already popular in functional and oncological neurosurgical laser interstitial thermal therapy (LITT) procedures.
The ClearPoint Prism system is currently approved for use with 3.0 T MRI guidance, where it is employed to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy, specifically in neurosurgery with a 1064 nm wavelength. The success of the FDA submission could further enhance the system's versatility and reach in medical and surgical applications.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for ClearPoint Neuro Inc (CLPT, Financial) is $27.67 with a high estimate of $30.00 and a low estimate of $25.00. The average target implies an upside of 88.21% from the current price of $14.70. More detailed estimate data can be found on the ClearPoint Neuro Inc (CLPT) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, ClearPoint Neuro Inc's (CLPT, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ClearPoint Neuro Inc (CLPT, Financial) in one year is $15.61, suggesting a upside of 6.19% from the current price of $14.7. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ClearPoint Neuro Inc (CLPT) Summary page.
CLPT Key Business Developments
Release Date: February 26, 2025
- Total Revenue (2024): $31.4 million, a 31% increase from $24 million in 2023.
- Biologics and Drug Delivery Revenue (2024): $17.3 million, up 27% from $13.6 million in 2023.
- Neurosurgery Navigation Revenue (2024): $10.3 million, a 21% increase from 2023.
- Capital Equipment and Software Revenue (2024): $3.8 million, a 107% increase from 2023.
- Gross Margin (2024): 61%, up from 57% in 2023.
- Research and Development Costs (2024): $12.4 million, a 6% increase from $11.7 million in 2023.
- Sales and Marketing Expenses (2024): $14.5 million, a 15% increase from $12.6 million in 2023.
- General and Administrative Expenses (2024): $12 million, a 2% increase from $11.8 million in 2023.
- Net Interest Income (2024): $0.9 million.
- Cash and Cash Equivalents (End of 2024): $20.1 million, down from $23.1 million at the end of 2023.
- Operational Cash Burn (2024): $9 million, a 35% reduction from 2023.
- Equity Offering (March 2024): Net proceeds of $16.2 million, used to retire outstanding debt.
- Revenue Guidance (2025): Expected between $36 million and $41 million, representing growth between 15% and 31%.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- ClearPoint Neuro Inc (CLPT, Financial) reported a 31% increase in total revenues for 2024, reaching $31.4 million, driven by growth across all business segments.
- The company successfully launched new MR navigation systems, operating room navigation systems, and other technologies, enhancing their product portfolio and customer adoption.
- ClearPoint Neuro Inc (CLPT) achieved a gross margin increase to 61% in 2024, up from 57% in 2023, due to lower costs and higher volumes.
- The company expanded its global footprint with 25 new global customer activations in 2024, more than tripling its historical average.
- ClearPoint Neuro Inc (CLPT) is debt-free as of December 2024, following an equity offering that strengthened its balance sheet.
Negative Points
- Operating expenses increased to $10.4 million in Q4 2024, up from $8.7 million in Q4 2023, driven by increased headcount and share-based compensation.
- Cash and cash equivalents decreased to $20.1 million at the end of 2024, down from $23.1 million at the end of 2023, primarily due to operating cash needs.
- The company faces uncertainty in the timing of preclinical GLP expansion, which could impact revenue growth in 2025.
- Capital equipment product and related service revenue saw a slight decrease in Q4 2024 compared to the same period in 2023.
- ClearPoint Neuro Inc (CLPT) anticipates a wide revenue growth range of 15% to 31% for 2025, indicating potential variability in achieving targets.
